Emergent BioSolutions Reports Financial Results For First Quarter 2022 : vimarsana.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

Canada , United States , Canadian , Robert Burrows , Robertg Kramer , Grossmarginiscalculatedasrevenuelesscostofsales Grossmargin , Keith Katkin , Coleen Glessner , Zsolt Harsanyi , Matt Hartwig , Joseph Philipose , Johnson , Instagram , Contract Development , Linkedin , Twitter , Emergent Biosolutions Inc , Development Expenses , Company Rockville , Reconciliation Of Net Research , Us Department Of Health , Biomedical Advanced Research , Human Services , Drug Administration , Development Authority , Exchange Commission , Net Research , Research Institute , Strategic National Stockpile , Company Camden , Net Income , Gross Margin , Biologics License Application , Anthrax Vaccine Adsorbed , Global Quality , Chief Ethics , Compliance Officer , Southwest Research , Nasal Spray , Anthrax Immune Globulin Intravenous , Advanced Development , Product Sales , Medical Countermeasure , Business Secured , Anthrax Vaccines , Nasal Naloxone , Eastern Time , Teleconference Information , Webcast Information , Adjusted Net Income , Earnings Before Interest , Adjusted Gross Margin , Adjusted Product Gross Margin , Adjusted Revenues , Adjusted Gross , Private Securities Litigation Reform Act , Current Good Manufacturing Practices , Senior Unsecured Notes , Investor Relations , Media Relations , Consolidated Statements , Months Ended March , Cash Flows , Covid 19 , Business , Health , Public Health , Globe Newswire ,